What Is Another Name for Tirzepatide? Every Brand, Generic, and Compounded Version Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is the International Nonproprietary Name (INN); Mounjaro and Zepbound are the FDA-approved brand names for diabetes and weight loss respectively
• No FDA-approved generic tirzepatide exists as of April 2026, and none is expected before 2032 due to patent protection
• Compounded tirzepatide uses the same active ingredient but is prepared by state-licensed pharmacies and is not FDA-approved
• International markets use different brand names including Manjaro (China) and country-specific versions pending approval in the EU, UK, and Canada

Direct answer (40-60 words)

Tirzepatide is sold under two FDA-approved brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight management). The medication is also available as compounded tirzepatide from licensed U.S. compounding pharmacies. No FDA-approved generic exists. International markets use region-specific brand names, though most countries outside the U.S. have not yet approved the medication.

Table of contents

1. The naming hierarchy: INN vs brand vs generic
2. Mounjaro vs Zepbound: same drug, different FDA indications
3. Why no generic tirzepatide exists (and when to expect one)
4. Compounded tirzepatide: what the name means legally
5. International brand names and approval status by region
6. What most articles get wrong about "generic" tirzepatide
7. The FormBlends naming convention for compounded products
8. Street names and patient shorthand you'll see online
9. How to verify what you're actually getting
10. The trademark landscape and why it matters
11. FAQ
12. Sources

The naming hierarchy: INN vs brand vs generic

Every medication has multiple names operating at different levels of the naming system. Understanding the hierarchy prevents confusion when researching tirzepatide.

International Nonproprietary Name (INN): tirzepatide

The INN is the official scientific name assigned by the World Health Organization. It's the name used in research papers, prescribing information, and regulatory documents worldwide. "Tirzepatide" is the INN. It never changes regardless of manufacturer or country.

The INN follows WHO naming conventions. The "-tide" suffix indicates a peptide structure. The "tirze-" prefix is arbitrary but designed to be distinct from other peptide medications. Semaglutide, dulaglutide, and liraglutide follow the same suffix pattern because they're all GLP-1 receptor agonist peptides.

Brand names (trade names): Mounjaro, Zepbound

Brand names are proprietary trademarks owned by the manufacturer. Eli Lilly owns both Mounjaro and Zepbound. These names are specific to the U.S. market. Other countries where Lilly sells tirzepatide may use different brand names.

Brand names are chosen for marketing reasons. "Mounjaro" evokes Mount Kilimanjaro, suggesting a peak or summit (the implication being peak glucose control). "Zepbound" suggests being bound for a destination, with "zep-" phonetically similar to "step" (weight-loss journey language).

The FDA allows the same drug to have multiple brand names if the indications differ. Mounjaro is approved for type 2 diabetes at doses of 2.5 mg to 15 mg. Zepbound is approved for chronic weight management at doses of 2.5 mg to 15 mg. The formulation is identical; the indication and prescribing information differ.

Generic name: none exists

A generic is a copy of a brand-name drug manufactured after patent expiration. No FDA-approved generic tirzepatide exists as of April 2026. When one eventually launches, it will be labeled "tirzepatide" (the INN) without a brand name, manufactured by a company other than Lilly.

Compounded name: compounded tirzepatide

Compounded medications use the INN plus the word "compounded." This distinguishes them from FDA-approved products. Compounded tirzepatide is tirzepatide prepared by a state-licensed compounding pharmacy under an individual prescription. It is not FDA-approved and is not a generic.

Mounjaro vs Zepbound: same drug, different FDA indications

Mounjaro and Zepbound contain identical tirzepatide formulations. The distinction is regulatory, not chemical.

Mounjaro (approved May 2022)

• Indication: Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control
• Dosing: 2.5 mg starting dose, escalate to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg based on glycemic response
• Prescribing information: Emphasizes A1C reduction, fasting glucose, and cardiovascular risk factors
• Insurance coding: Billed as a diabetes medication; prior authorization requirements focus on diabetes diagnosis and metformin failure

Zepbound (approved November 2023)

• Indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
• Dosing: 2.5 mg starting dose, escalate to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg based on weight-loss response and tolerability
• Prescribing information: Emphasizes weight reduction, waist circumference, and cardiometabolic improvements
• Insurance coding: Billed as a weight-management medication; prior authorization requirements focus on BMI and documented lifestyle intervention attempts

The clinical trials supporting each approval were different. Mounjaro's approval relied on the SURPASS trial program (SURPASS-1 through SURPASS-5), which enrolled patients with type 2 diabetes. Zepbound's approval relied on the SURMOUNT trial program (SURMOUNT-1 through SURMOUNT-4), which enrolled patients with obesity or overweight, most of whom did not have diabetes.

The average weight loss in SURMOUNT-1 at the 15 mg dose was 20.9% of body weight over 72 weeks (Jastreboff et al., New England Journal of Medicine, 2022). The average A1C reduction in SURPASS-2 at the 15 mg dose was 2.46 percentage points compared to 1.86 points for semaglutide 1 mg (Frías et al., New England Journal of Medicine, 2021).

Patients and providers sometimes use the names interchangeably, which creates confusion in insurance billing. A prescription written for "Mounjaro for weight loss" will be rejected by most insurers because Mounjaro's FDA-approved indication is diabetes. The prescription must specify Zepbound for weight management or Mounjaro for diabetes to match the indication to the brand name.

Why no generic tirzepatide exists (and when to expect one)

Tirzepatide is protected by multiple patents that prevent generic manufacturers from entering the market until expiration.

The primary composition-of-matter patent (U.S. Patent 9,732,139) expires in 2032. This patent covers the tirzepatide molecule itself. No generic manufacturer can produce tirzepatide in the U.S. until this patent expires or is successfully challenged.

Lilly holds additional patents covering manufacturing processes, formulation methods, and specific uses that extend protection further. The last of these patents expires in 2036. In practice, the first generic tirzepatide is unlikely to launch before 2033 to 2035, depending on patent litigation and FDA approval timelines.

For comparison, semaglutide's primary patent (held by Novo Nordisk) expires in 2031. The first generic semaglutide is expected around 2032 to 2033.

Biologics like tirzepatide follow a different regulatory pathway than small-molecule drugs. When the patent expires, generic manufacturers will file Abbreviated New Drug Applications (ANDAs) demonstrating bioequivalence to the reference product. The FDA requires that generics deliver the same amount of active ingredient to the bloodstream within a defined range (typically 80% to 125% of the reference product's area under the curve).

Peptide drugs are harder to copy than small molecules because manufacturing processes affect the final product's structure and stability. Generic manufacturers must demonstrate that their version has the same amino acid sequence, the same folding pattern, the same purity profile, and the same stability as the brand-name product. This is why biologic generics (called biosimilars) take longer to develop and launch than small-molecule generics.

The price impact of generic entry is expected to be significant. Brand-name Mounjaro and Zepbound list prices are approximately $1,060 per month as of April 2026. Generic tirzepatide will likely launch at 30% to 50% of the brand price initially, dropping to 10% to 20% of the brand price once multiple generics are available, based on historical patterns for other peptide drugs.

Compounded tirzepatide: what the name means legally

Compounded tirzepatide is tirzepatide prepared by a state-licensed compounding pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. It is not an FDA-approved product and is not a generic.

The legal distinction matters. FDA-approved drugs undergo Phase 1, 2, and 3 clinical trials, manufacturing inspections, and ongoing post-market surveillance. Compounded medications are exempt from FDA approval requirements if they meet specific criteria:

1. Prepared in response to an individual patient prescription (503A) or in limited batches under cGMP conditions (503B)
2. Made by a state-licensed pharmacy or outsourcing facility
3. Not a copy of a commercially available FDA-approved drug, unless the FDA-approved version is on the FDA's drug shortage list

As of April 2026, tirzepatide is on the FDA drug shortage list, which allows compounding pharmacies to prepare compounded tirzepatide legally. If the shortage resolves and tirzepatide is removed from the list, compounding pharmacies must stop preparing it.

Compounded tirzepatide is labeled "compounded tirzepatide" or "tirzepatide injection (compounded)" on the vial. It is not labeled Mounjaro or Zepbound. Using a brand name on a compounded product is trademark infringement.

The active ingredient in compounded tirzepatide is the same peptide molecule as in Mounjaro and Zepbound. Compounding pharmacies source tirzepatide powder from FDA-registered suppliers (often the same suppliers that manufacture active pharmaceutical ingredients for brand-name drugs). The powder is reconstituted in bacteriostatic water or another sterile diluent and dispensed in multi-dose vials.

The difference between compounded and brand-name tirzepatide is in the formulation and quality assurance. Brand-name products are pre-filled single-dose pens with proprietary excipients and preservatives. Compounded products are multi-dose vials that require manual drawing and injection. Brand-name products undergo batch testing for potency, sterility, endotoxins, and particulates at an FDA-inspected facility. Compounded products are tested by the pharmacy or an independent lab, but testing standards vary.

The cost difference is significant. Compounded tirzepatide typically costs $200 to $400 per month depending on dose and pharmacy. Brand-name Mounjaro or Zepbound costs $1,060 per month without insurance.

International brand names and approval status by region

Tirzepatide is approved or under review in multiple countries outside the U.S. Each market uses region-specific brand names.

China

• Brand name: Manjaro (曼哲罗)
• Approval status: Approved December 2023 for type 2 diabetes
• Manufacturer: Eli Lilly (local subsidiary)
• Notes: First non-U.S. approval; weight-loss indication not yet approved

European Union

• Brand name: Mounjaro (same as U.S.)
• Approval status: Approved September 2022 for type 2 diabetes; weight-loss indication approved November 2024
• Manufacturer: Eli Lilly
• Notes: Available in UK, Germany, France, Spain, Italy; reimbursement varies by country

United Kingdom

• Brand name: Mounjaro (diabetes), Zepbound (weight loss, pending)
• Approval status: Approved for diabetes September 2022; weight-loss indication approved by MHRA March 2024 but not yet available due to supply constraints
• Manufacturer: Eli Lilly
• Notes: NHS reimbursement restricted to specific patient populations

Canada

• Brand name: Mounjaro
• Approval status: Approved April 2023 for type 2 diabetes; weight-loss indication under review
• Manufacturer: Eli Lilly
• Notes: Provincial formularies have not yet added tirzepatide to reimbursement lists

Japan

• Brand name: Maunjaro (マウンジャロ)
• Approval status: Approved April 2023 for type 2 diabetes
• Manufacturer: Eli Lilly Japan
• Notes: Weight-loss indication not submitted for approval

Australia

• Brand name: Mounjaro
• Approval status: Approved November 2023 for type 2 diabetes
• Manufacturer: Eli Lilly
• Notes: Not yet listed on Pharmaceutical Benefits Scheme (PBS); full out-of-pocket cost approximately AUD $500 per month

South Korea

• Brand name: Mounjaro
• Approval status: Approved August 2023 for type 2 diabetes
• Manufacturer: Eli Lilly Korea
• Notes: Reimbursement approved for patients with A1C ≥7.5% despite metformin therapy

Most international approvals are for the diabetes indication only. Weight-loss indications are under review or not yet submitted in most markets. The EU and UK are the only non-U.S. markets where tirzepatide is approved for weight management as of April 2026.

International patients ordering tirzepatide online may receive products labeled with any of the above brand names depending on the source country. Importing prescription medications into the U.S. without FDA approval is illegal under most circumstances.

What most articles get wrong about "generic" tirzepatide

The most common error in online content about tirzepatide names is conflating "compounded tirzepatide" with "generic tirzepatide." These are not the same.

The error: Many articles and patient forums describe compounded tirzepatide as "generic Mounjaro" or "generic Zepbound." This is legally and factually incorrect.

Why it's wrong: A generic drug is an FDA-approved copy of a brand-name drug that meets bioequivalence standards and is manufactured under FDA oversight. Compounded tirzepatide is not FDA-approved, does not undergo FDA bioequivalence testing, and is not subject to the same manufacturing standards as FDA-approved generics.

The FDA has issued warning letters to pharmacies and telehealth companies that market compounded tirzepatide as "generic" or imply equivalence to FDA-approved products. The distinction matters for patient safety and legal compliance.

What to say instead:

• "Compounded tirzepatide" (correct)
• "Non-branded tirzepatide" (acceptable)
• "Pharmacy-compounded tirzepatide" (correct)
• "Generic tirzepatide" (incorrect; no such product exists)

The second common error: Articles claim that compounded tirzepatide is "the same as" Mounjaro or Zepbound. This is an impermissible equivalency claim under FDA guidance.

Why it's wrong: Compounded products have not undergone the same testing as FDA-approved products. Potency, purity, and sterility can vary between compounding pharmacies and between batches from the same pharmacy. The FDA explicitly prohibits statements that compounded drugs are equivalent to or substitutes for FDA-approved drugs.

What to say instead:

• "Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound" (correct)
• "Compounded tirzepatide is tirzepatide prepared by a licensed pharmacy" (correct)
• "Compounded tirzepatide is the same as Mounjaro" (incorrect; impermissible equivalency claim)

The practical consequence of these errors is patient confusion about what they're receiving and whether it's been tested to the same standard as the brand-name product. Clarity in naming prevents misunderstanding.

The FormBlends naming convention for compounded products

FormBlends uses a standardized naming system for all compounded GLP-1 medications to maintain clarity and compliance.

Product labels:

• "Tirzepatide Injection (Compounded)"
• Dose concentration listed in mg/mL
• "For Subcutaneous Use Only"
• "Compounded by [Pharmacy Name], [State License Number]"
• "Not FDA-Approved"

Patient-facing materials:

• "Compounded tirzepatide" in all educational content
• Never "generic Mounjaro" or "generic Zepbound"
• Never "tirzepatide (Mounjaro)" or similar constructions that imply equivalence

Prescription routing:

• Providers write prescriptions for "tirzepatide, compounded" with dose and frequency
• Pharmacy dispenses as "Tirzepatide Injection (Compounded)"
• Insurance billing uses NDC codes specific to compounded products, not brand-name NDCs

Why the naming convention matters: The FDA monitors telehealth platforms and compounding pharmacies for impermissible equivalency claims. Platforms that market compounded products as "generic" or "the same as" brand-name drugs receive warning letters and face enforcement action.

FormBlends's naming convention is designed to be factually accurate, legally compliant, and clear to patients. Patients know they are receiving a compounded product, understand that it is not FDA-approved, and can make an informed decision about whether to use it.

Street names and patient shorthand you'll see online

Patients in online forums and social media groups use informal shorthand for tirzepatide that differs from official names.

Common patient shorthand:

• "Tirz" (pronounced "teerz")
• "MJ" (Mounjaro)
• "ZB" (Zepbound)
• "Compound tirz"
• "The mountain" (reference to Mounjaro/Kilimanjaro)

Why patients use shorthand: GLP-1 medication discussions happen in Facebook groups, Reddit forums, and Discord servers where typing full drug names repeatedly is cumbersome. Shorthand also provides a degree of privacy when discussing weight-loss medication in semi-public spaces.

Risks of shorthand: Shorthand can create confusion when patients switch between brand-name and compounded products. A patient asking "Is tirz the same as MJ?" may not realize they're asking whether compounded tirzepatide is the same as brand-name Mounjaro, which is the equivalency question discussed above.

Providers and pharmacies should use full official names in all written communication to avoid ambiguity. Patient education materials should define shorthand terms if they appear in quoted patient questions but use official names in answers.

How to verify what you're actually getting

Patients switching between brand-name and compounded tirzepatide, or ordering from new pharmacies, should verify they're receiving the correct product.

For brand-name Mounjaro or Zepbound:

1. Check the pen packaging for the Lilly logo and brand name
2. Verify the NDC (National Drug Code) on the box matches the NDC on your prescription label
3. Mounjaro NDC format: 00002-XXXX-XX (Lilly's manufacturer code is 00002)
4. Zepbound NDC format: 00002-XXXX-XX (same manufacturer code)
5. Pens should be pre-filled, single-dose, and color-coded by dose strength
6. Verify the lot number and expiration date are printed on the pen and box

For compounded tirzepatide:

1. Check the vial label for "Compounded" or "Compounded by [Pharmacy Name]"
2. Verify the pharmacy name and state license number on the label
3. Confirm the label states "Not FDA-Approved"
4. Verify the dose concentration (mg/mL) matches your prescription
5. Check for a beyond-use date (BUD), not an expiration date (compounded products have shorter stability windows)
6. Verify the vial is sealed and the solution is clear and colorless (no particulates or cloudiness)

Red flags:

• A vial labeled "Mounjaro" or "Zepbound" (brand names should only appear on Lilly pens, not compounded vials)
• No pharmacy name or license number on the label
• No "Not FDA-Approved" disclaimer on compounded products
• Vials shipped from outside the U.S.
• Suspiciously low prices (compounded tirzepatide below $150/month or brand-name below $900/month without insurance suggests counterfeit risk)

Certificate of Analysis (COA): Reputable compounding pharmacies provide a Certificate of Analysis for each batch showing third-party testing results for potency, sterility, and endotoxins. Patients can request a COA from the pharmacy. If the pharmacy refuses or cannot provide one, consider switching pharmacies.

The trademark landscape and why it matters

Eli Lilly holds registered trademarks for Mounjaro (U.S. Trademark Reg. No. 6,734,512) and Zepbound (U.S. Trademark Reg. No. 7,128,403). Unauthorized use of these trademarks is infringement.

What constitutes infringement:

• Labeling a compounded product "Mounjaro" or "Zepbound"
• Marketing compounded tirzepatide as "generic Mounjaro"
• Using Lilly's brand names in advertising without authorization
• Suggesting affiliation with or endorsement by Lilly

What does not constitute infringement:

• Educational comparison ("Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound")
• Factual statements about indications ("Mounjaro is FDA-approved for type 2 diabetes")
• Nominative use in patient questions ("Is compounded tirzepatide the same as Mounjaro?")

Lilly actively enforces its trademarks. The company has sent cease-and-desist letters to compounding pharmacies and telehealth platforms that misuse brand names. Continued infringement can result in lawsuits and injunctions.

For patients, the trademark landscape means you should be skeptical of any seller offering "Mounjaro" at compounded prices. If it's labeled Mounjaro, it should be a Lilly pen at brand-name pricing. If it's a compounded vial, it should be labeled "compounded tirzepatide," not Mounjaro.

FAQ

What is the generic name for tirzepatide? Tirzepatide is the generic name (International Nonproprietary Name). No FDA-approved generic version of tirzepatide exists as of April 2026. The brand names are Mounjaro and Zepbound.

Is Mounjaro the same as Zepbound? Yes, both contain the same tirzepatide formulation. The difference is the FDA-approved indication: Mounjaro is for type 2 diabetes, Zepbound is for weight management. The dosing schedules and prescribing information differ slightly.

What is compounded tirzepatide called? Compounded tirzepatide is labeled "Tirzepatide Injection (Compounded)" or similar variations. It is not called Mounjaro or Zepbound. It is not a generic; it is a pharmacy-compounded preparation.

When will generic tirzepatide be available? The first FDA-approved generic tirzepatide is expected around 2033 to 2035, after Lilly's primary patents expire in 2032 and generic manufacturers complete FDA approval processes.

Is compounded tirzepatide the same as Mounjaro? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved and is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. The two products are not interchangeable.

What is tirzepatide called in other countries? Mounjaro in most markets (EU, UK, Canada, Australia, South Korea), Manjaro in China, and Maunjaro in Japan. Brand names vary by region but all contain the same tirzepatide molecule.

Can I use the name Mounjaro for compounded tirzepatide? No. Mounjaro is a registered trademark owned by Eli Lilly. Using it to describe compounded tirzepatide is trademark infringement and creates patient confusion about what product you're receiving.

What does the "tirz" abbreviation mean? "Tirz" is patient shorthand for tirzepatide used in online forums and social media groups. It is not an official name and should not be used in prescriptions or medical records.

Is Zepbound just Mounjaro rebranded for weight loss? Essentially, yes. Zepbound is the same tirzepatide formulation as Mounjaro but approved under a different indication (weight management instead of diabetes). The clinical trial data supporting each approval came from different study populations.

What is the difference between 503A and 503B compounded tirzepatide? 503A compounded tirzepatide is prepared by a traditional compounding pharmacy in response to individual prescriptions. 503B compounded tirzepatide is prepared by an outsourcing facility in limited batches under FDA-registered cGMP conditions. Both are compounded products; 503B facilities have more stringent quality requirements.

Why do some pharmacies call it "semaglutide/tirzepatide" in one product? Some compounding pharmacies offer combination products containing both semaglutide and tirzepatide in a single vial. This is an off-label compounded formulation not supported by clinical trial data. The name reflects both active ingredients.

Can I get tirzepatide under a different name to avoid insurance issues? No. Insurance billing requires accurate coding. A prescription for Mounjaro must be for the diabetes indication; a prescription for Zepbound must be for the weight-management indication. Compounded tirzepatide is billed separately with compounded product codes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. U.S. Food and Drug Administration. Mounjaro Prescribing Information. 2022.
4. U.S. Food and Drug Administration. Zepbound Prescribing Information. 2023.
5. World Health Organization. International Nonproprietary Names (INN) for Pharmaceutical Substances. 2024.
6. U.S. Patent and Trademark Office. Patent No. 9,732,139 (Tirzepatide composition). 2017.
7. U.S. Patent and Trademark Office. Trademark Registration No. 6,734,512 (Mounjaro). 2022.
8. U.S. Patent and Trademark Office. Trademark Registration No. 7,128,403 (Zepbound). 2023.
9. U.S. Food and Drug Administration. Drug Shortages Database (Tirzepatide). Updated April 2026.
10. European Medicines Agency. Mounjaro Assessment Report. 2022.
11. Medicines and Healthcare products Regulatory Agency (UK). Mounjaro Public Assessment Report. 2022.
12. National Medical Products Administration (China). Manjaro Approval Notice. 2023.
13. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
14. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners (Eli Lilly and Company, Novo Nordisk). FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.